Synergistic activities of meropenem double and triple combinations against carbapenemase-producing Enterobacteriaceae

Diagnostic Microbiology and Infectious Disease

Volumn 88, Issue 4, 2017, Pages 355-360

  Fredborg, Marlene ^a,c   Sondergaard, Teis E ^b   Wang, Mikala ^c  

^a AARHUS UNIVERSITY   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antibiotics; Carbapenem resistance; Klebsiella pneumoniae; Time lapse microscopy

Indexed keywords

AMIKACIN; COLISTIN; DORIPENEM; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; POLYMYXIN B; RIFAMPICIN; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAM; BETA LACTAMASE; CARBAPENEMASE; POLYMYXIN; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG EFFECTS; HUMAN; METABOLISM;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG SYNERGISM; HUMANS; POLYMYXINS; RIFAMPIN; THIENAMYCINS;

EID: 85020060986     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2017.04.015     Document Type: Article

References (40)

1. Akova, M., Daikos, G.L., Tzouvelekis, L., Carmeli, Y., Interventional strategies and current clinical experience with carbapenemase-producing gram-negative bacteria. Clin Microbiol Infect 18 (2012), 439–448.
2. Bulik, C.C., Nicolau, D.P., Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 55 (2011), 3002–3004.
3. Bush, K., Jacoby, G.A., Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 54 (2010), 969–976.
4. Cantón, R., Ruiz-Garbajosa, P., Co-resistance: an opportunity for the bacteria and resistance genes. Curr Opin Pharmacol 11 (2011), 477–485.
5. Ceccarelli, G., Falcone, M., Giordano, A., Mezzatesta, M.L., Caio, C., Stefani, S., et al. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 57 (2013), 2900–2901.
6. Conte, J.E., Golden, J.A., Kelley, M.G., Zurlinden, E., Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents 26 (2005), 449–456.
7. Fredborg, M., Andersen, K.R., Jorgensen, E., Droce, A., Olesen, T., Jensen, B.B., et al. Real-time optical antimicrobial susceptibility testing. J Clin Microbiol 51 (2013), 2047–2053.
8. Fredborg, M., Rosenvinge, F.S., Spillum, E., Kroghsbo, S., Wang, M., Sondergaard, T.E., Rapid antimicrobial susceptibility testing of clinical isolates by digital time-lapse microscopy. Eur J Clin Microbiol 34 (2015), 2385–2394.
9. Fredborg, M., Rosenvinge, F.S., Spillum, E., Kroghsbo, S., Wang, M., Sondergaard, T.E., Automated image analysis for quantification of filamentous bacteria. BMC Microbiol 15 (2015), 1–8.
10. Garonzik, S.M., Li, J., Thamlikitkul, V., Paterson, D.L., Shoham, S., Jacob, J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55 (2011), 3284–3294.
11. Glasner, C., Albiger, B., Buist, G., Tambic Andrasevic, A., Canton, R., Carmeli, Y., et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill, 18, 2013, 20525.
12. Hong, J.H., Clancy, C.J., Cheng, S., Shields, R.K., Chen, L., Doi, Y., et al. Characterization of porin expression in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems. Antimicrob Agents Chemother 57 (2013), 2147–2153.
13. Hu, L., Zhong, Q., Shang, Y., Wang, H., Ning, C., Li, Y., et al. The prevalence of carbapenemase genes and plasmid-mediated quinolone resistance determinants in carbapenem-resistant Enterobacteriaceae from five teaching hospitals in central. China Epidemiol Infect 142 (2014), 1972–1977.
14. Lim, T.P., Cai, Y., Hong, Y., Chan, E.C.Y., Suranthran, S., Teo, J.Q.-M., et al. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 59 (2015), 2515–2524.
15. Matzi, V., Lindenmann, J., Porubsky, C., Kugler, S.A., Maier, A., Dittrich, P., et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother 65 (2010), 995–998.
16. Meagher, A.K., Ambrose, P.G., Grasela, T.H., Ellis-Grosse, E.J., Pharmacokinetic/pharmacodynamic profile for tigecycline - a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 52 (2005), 165–171.
17. Morrill, H.J., Pogue, J.M., Kaye, K.S., LaPlante, K.L., Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis, 2015, 10.1093/ofid/ofv050.
18. Munoz-Price, L.S., Poirel, L., Bonomo, R.A., Schwaber, M.J., Daikos, G.L., Cormican, M., et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13 (2013), 785–796.
19. Nabarro, L.E.B., Veeraraghavan, B., Combination therapy for carbapenem-resistant Enterobacteriaceae: increasing evidence, unanswered questions, potential solutions. Eur J Clin Microbiol 34 (2015), 2307–2311.
20. Nordmann, P., Thierry, N., Laurent, P., Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17 (2011), 1791–1798.
21. Nordmann, P., Gniadkowski, M., Giske, C.G., Poirel, L., Woodford, N., Miriagou, V., Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 18 (2012), 432–438.
22. Oliva, A., D'Abramo, A., D'Agostino, C., Iannetta, M., Mascellino, M.T., Gallinelli, C., et al. Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections. J Antimicrob Chemother 69 (2014), 1718–1720.
23. Özseven, A.G., Cetin, E.S., Aridogan, B.C., Özseven, L., In vitro synergistic activity of carbapenems in combination with other antimicrobial agents against multidrug-resistant Acinetobacter Baumannii. Antimicrob Agents Chemother, 2012, 10.5897/AJMR12.038.
24. Pillai, S.K., Moellering, R.C., Eliopoulos, G.M., Antimicrobial combinations. Lorian, V., (eds.) Antibiotics in laboratory medicine, 5th ed., 2005, Lippincott Williams & Wilkins, Philadelphia, USA, 365–440.
25. Poirel, L., Kieffer, N., Nordmann, P., In vitro evaluation of dual carbapenem combinations against carbapenemase-producing. J Antimicrob Chemother 71 (2015), 156–161.
26. Queenan, A.M., Bush, K., Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20 (2007), 440–458.
27. Samonis, G., Maraki, S., Karageorgopoulos, D.E., Vouloumanou, E.K., Falagas, M.E., Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas Aeruginosa clinical isolates. Eur J Clin Microbiol 31 (2012), 695–701.
28. Sanchez, G.V., Master, R.N., Clark, R.B., Fyyaz, M., Duvvuri, P., Ekta, G., et al. Klebsiella pneumoniae Antimicrobial drug resistance, United States, 1998-2010. Emerg Infect Dis 19 (2013), 133–136.
29. Souli, M., Galani, I., Boukovalas, S., Gourgoulis, M.G., Chryssouli, Z., Kanellakopoulou, K., et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother 55 (2011), 2395–2397.
30. Tängdén, T., Giske, C.G., Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med 277 (2015), 501–512.
31. Tängdén, T., Hickman, R.A., Forsberg, P., Lagerbäck, P., Giske, C.G., Cars, O., Evaluation of double-and triple-antibiotic combinations for VIM-and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 58 (2014), 1757–1762.
32. Toussaint, K.A., Gallagher, J.C., Beta-lactam/Beta-lactamase inhibitor combinations from then to now. Ann Pharmacother, 2014, 10.1177/1060028014556652.
33. Tzouvelekis, L.S., Markogiannakis, A., Psichogiou, M., Tassios, P.T., Daikos, G.L., Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 25 (2012), 682–707.
34. Tzouvelekis, L.S., Markogiannakis, A., Piperaki, E., Souli, M., Daikos, G.L., Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 20 (2014), 862–872.
35. Urban, C., Mariano, N., Rahal, J.J., In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter Baumannii, Pseudomonas Aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 54 (2010), 2732–2734.
36. Walker, C.D., Shankaran, S., Extended antibiotic resistance in carbapenemase-producing Klebsiella pneumoniae: a case series. Am J Infect Control 44 (2016), 1050–1052.
37. Walsh, T.R., Toleman, M.A., Poirel, L., Nordmann, P., Metallo-beta-lactamases: the quiet before the storm?. Clin Microbiol Rev 18 (2005), 306–325.
38. Watkins, R.R., Deresinski, S., Is combination therapy for carbapenem-resistant Klebsiella pneumoniae the new standard of care?. Expert Rev Anti Infect Ther 13 (2015), 405–407.
39. Yoon, J., Urban, C., Terzian, C., Mariano, N., Rahal, J.J., In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter Baumannii. Antimicrob Agents Chemother 48 (2004), 753–757.
40. Zusman, O., Avni, T., Leibovici, L., Adler, A., Friberg, L., Stergiopoulou, T., et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 57 (2013), 5104–5111.